Main Menu

The technology focuses on developing clonal lineage antibodies targeting the CD4 binding site of HIV-1, serving as templates for an effective HIV-1 vaccine. Developed through collaboration with Duke, Boston, and Stanford Universities, the patent filed by Duke University in 2012. These antibodies exhibit neutralizing activity against HIV-1, designed for therapeutic and prophylactic benefits, targeting a critical site of vulnerability on the virus to stimulate the immune system.

The development of an infectious molecular clone of simian immunodeficiency virus SIVsm, known as SIVsmE543-3, marks a significant breakthrough in SIV research. This clone, derived from a late-stage biological isolate from an immunodeficient rhesus macaque with SIV-induced encephalitis, has shown robust replication in macaque immune cells and macrophages. Notably, SIVsmE543-3 exhibits resistance to neutralization by heterologous sera, which can typically neutralize genetically diverse SIV variants in vitro.

This innovative technology represents a significant advancement in the field of HIV-1 therapy and prevention. By targeting a second, quaternary CD4-binding site with the engraftment of the VRC03 FR3 loop, it enhances the potency of broadly neutralizing antibodies against HIV-1. Importantly, this approach also addresses issues of autoreactivity and extends the antibody's half-life in vivo.

The technology focuses on stabilizing the respiratory syncytial virus (RSV) fusion (F) glycoprotein in its prefusion conformation, crucial for developing effective RSV vaccines. By introducing specific mutations (S155C-S290C, S190F, V207L) and creating interprotomer disulfides, trimer stabilization is achieved without relying on a foldon domain. This innovative approach enhances the immunogenicity of the RSV F protein, potentially leading to more potent and focused immune responses against RSV.

The development of 5C4, a monoclonal antibody targeting the prefusion conformation of the Respiratory Syncytial Virus (RSV) Fusion (F) glycoprotein, represents a significant advancement in RSV vaccine research. Unlike the postfusion state, the prefusion conformation of the F glycoprotein contains unique epitopes targeted by neutralizing antibodies.

The technology outlined in the document is focused on the discovery of novel biomarkers for Onchocerciasis, a parasitic disease also known as river blindness, which is transmitted by blackfly vectors. The document describes the identification of the first Onchocerca volvulus-encoded molecules that are adult-specific and can be used as markers for macrofilaricidal activity, which is the ability to kill adult worms.

The technology is centered around the Real Time Quaking Induced Conversion (RT-QuIC) assay, which aims to enhance the detection and discrimination of prion diseases in humans and animals. This assay utilizes recombinant prion protein (rPrPSen) to detect prion-seeded fibrillization, offering a highly specific and ultra-sensitive method for detecting multiple prion diseases across various species. A key innovation of the technology is the use of recombinant bank vole prion protein as a broadly reactive substrate. This substrate, when expressed in E.

This technology represents a groundbreaking approach to combating Ebola virus disease (EVD) by targeting key host cell signaling pathways implicated in the pathogenesis of the disease. Through innovative investigational strategies, the technology has identified specific kinase inhibitors that effectively reduce EVD progression in both cell culture and animal models. By focusing on pathways related to cell growth, survival, proliferation, and anti-apoptotic responses, this approach offers a novel therapeutic avenue for EVD treatment.

The N6 antibody represents a significant advancement in the quest for an effective HIV-1 vaccine. This novel antibody, isolated from B-cells of an HIV-1 infected individual, demonstrates potent and broad neutralizing activity against a wide range of HIV-1 isolates, including those resistant to other potent antibodies. N6 targets the CD4 binding site on the HIV envelope glycoprotein, particularly in the D-loop region, and exhibits higher potency than previously discovered antibodies like VRC01.

The technology pertains to the enhancement of HIV neutralizing antibodies, specifically VRC01, VRC07, and 10E8, which have been isolated and characterized for their potent antiviral activity. These antibodies have undergone specific mutations to improve their breadth and potency against a range of HIV strains. The aim is to extend their half-life, augment their in vivo effectiveness, and reduce immunogenicity.